These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6218576)

  • 1. Moxalactam in serious infections: clinical, bacteriologic, and pharmacokinetic studies.
    Giamarellou H; Tsagarakis J; Daikos GK
    Rev Infect Dis; 1982; 4 Suppl():S629-38. PubMed ID: 6218576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
    Fitzpatrick BJ; Standiford HC
    Pharmacotherapy; 1982; 2(4):197-212. PubMed ID: 6221237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drug evaluations: moxalactam (Moxam, Eli Lilly).
    Polk RE
    Drug Intell Clin Pharm; 1982 Feb; 16(2):104-12. PubMed ID: 6210519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of lower respiratory tract infections with moxalactam.
    Lentino JR; Rytel MW; Moore E
    Antimicrob Agents Chemother; 1981 May; 19(5):801-6. PubMed ID: 6457557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxalactam therapy for bacterial infections.
    Winston DJ; Busuttil RW; Kurtz TO; Young LS
    Arch Intern Med; 1981 Nov; 141(12):1607-12. PubMed ID: 6458253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of serious infections with moxalactam.
    Ribner BS; Raeder R; Becker TM; Freimer EH
    Am J Med; 1983 Mar; 74(3):396-400. PubMed ID: 6219576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxalactam therapy for a wide spectrum of bacterial infections in adults.
    Tofte RW; Rotschafer J; Solliday J; Crossley KB
    Antimicrob Agents Chemother; 1981 May; 19(5):740-4. PubMed ID: 6457555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vitro activity of moxalactam against 430 clinical, bacterial isolates.
    Digranes A; Benonisen E; Dibb WL; Ostervold B
    Acta Pathol Microbiol Immunol Scand B; 1982 Feb; 90(1):69-72. PubMed ID: 6211028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity, efficacy, and pharmacology of moxalactam, a new beta-lactam antibiotic.
    Snepar R; Poporad G; Romano J; Levison ME
    Antimicrob Agents Chemother; 1981 Nov; 20(5):642-7. PubMed ID: 6459763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of moxalactam.
    Mathisen GE; Meyer RD; Thompson JM; Finegold SM
    Antimicrob Agents Chemother; 1982 May; 21(5):780-6. PubMed ID: 6213198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal insufficiency.
    Trager GM; Panwalker AP; Malow JB; Porembski PE; Ramirez CA; Zar FA
    Chemotherapy; 1981; 27(4):287-95. PubMed ID: 6454542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo antibacterial activity of moxalactam, an oxa-beta-lactam antibiotic.
    Goto S
    Rev Infect Dis; 1982; 4 Suppl():S501-10. PubMed ID: 6218559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
    Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
    Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and clinical efficacy of moxalactam in biliary tract infections.
    Mueller O; Fabricius K; Krueger E; Rueckert U
    Rev Infect Dis; 1982; 4 Suppl():S688-91. PubMed ID: 6218584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Moxalactam and cefotaxime--two new beta-lactam antibiotics compared with three well-known cephalosporins].
    Baumgärtner M; Dickgiesser N; Müller S; Wundt W
    Arzneimittelforschung; 1981; 31(10):1677-81. PubMed ID: 6274361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of 18 cases of purulent meningitis with moxalactam. Pharmacokinetic data].
    Modai J; Vittecoq D; Decazes JM; Wolff M; Meulemans A
    Presse Med; 1983 Jan; 12(3):139-42. PubMed ID: 6220351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
    Eickhoff TC; Ehret J
    Antimicrob Agents Chemother; 1981 Mar; 19(3):435-42. PubMed ID: 6264845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 Jun; 17(6):937-42. PubMed ID: 6250470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and cerebrospinal fluid penetration of moxalactam in children and dosage recommendations.
    Kaplan SL; Mason EO; Kvernland SJ; Calaway EL; Feigin RD
    Rev Infect Dis; 1982; 4 Suppl():S597-602. PubMed ID: 6218570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.